San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor from the weight loss drug current market in February just after revealing promising knowledge from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied as a weekly injection As well as